Iontophoresis: Electrical Peptide Skin Delivery

Transdermal Peptide Delivery

1.25x Muscle Growth

Iontophoretic delivery of a myostatin-inhibitory peptide produced a 1.25-fold increase in skeletal muscle weight in preclinical studies, the first demonstration of biomolecule delivery to deep tissue through electrically assisted skin transport.

Yang et al., 2026

Yang et al., 2026

View as image

Most therapeutic peptides are delivered by injection because they are too large and too polar to cross the skin barrier on their own. Iontophoresis offers an alternative: a mild electric current (typically 0.1-0.5 mA/cm2) applied across the skin drives charged peptide molecules through the stratum corneum and into deeper tissue. The approach is non-invasive, controllable, and has been studied since the mid-1990s for peptide drug delivery.^[1] For context on other non-injection delivery methods, see the pillar article on microneedle patches for peptide delivery.

The appeal is straightforward: patients dislike injections, and poor adherence to injectable peptide therapies (insulin, GLP-1 agonists, growth hormone) is a well-documented clinical problem. Iontophoresis could transform peptides that currently require daily or weekly injections into patch-based therapies that patients apply at home. The technology has advanced substantially in recent years, with wearable devices, combination approaches (iontophoresis plus microneedles), and AI-optimized carrier peptides all expanding what is possible. This article covers how iontophoresis works, what peptides have been delivered through it, and where the technology stands.

How Iontophoresis Works

The skin's outermost layer, the stratum corneum, is a 10-20 micrometer thick barrier of dead, keratinized cells embedded in a lipid matrix. It is designed to keep foreign molecules out. For peptides, which are typically large (500-5,000 daltons), hydrophilic, and charged at physiological pH, passive diffusion across this barrier is negligible.

Iontophoresis overcomes this by two mechanisms.^[1]

Electromigration is the primary driving force. An electric field is applied between two electrodes placed on the skin surface. Positively charged peptides migrate from the anode (positive electrode) toward the cathode, driven through the stratum corneum by the electric field. Negatively charged peptides travel in the opposite direction. The transport rate is proportional to the applied current, giving the clinician direct control over drug delivery rate.

Electroosmosis is a secondary mechanism. The electric current generates bulk fluid flow through the skin's aqueous pores, carrying dissolved peptides along with it regardless of their charge. This convective transport is particularly important for larger peptides that would otherwise be too bulky for electromigration alone.

The current densities used (0.1-0.5 mA/cm2) are well below the threshold for pain or tissue damage. Patients typically feel a mild tingling sensation. The FDA has cleared iontophoretic devices for delivery of small molecules (lidocaine, dexamethasone) for decades, establishing the safety profile of the underlying technology. LidoSite (iontophoretic lidocaine) and Ionsys (iontophoretic fentanyl) are examples of FDA-cleared products that demonstrate the commercial viability of iontophoretic drug delivery, though both deliver small molecules rather than peptides.

Applying this technology to peptides introduces additional challenges. Peptides are larger (typically 500-5,000 daltons versus under 500 daltons for most small molecules), carry heterogeneous charges depending on their amino acid composition and pH, and are susceptible to enzymatic degradation by skin proteases that small molecules are not. These challenges mean that iontophoretic parameters optimized for small molecules cannot simply be transferred to peptide delivery without modification.

What Peptides Have Been Delivered

KPV: Anti-Inflammatory Tripeptide

Pawar et al. (2017) conducted one of the most detailed studies of peptide iontophoresis, delivering the tripeptide KPV (lysine-proline-valine) across dermatomed human skin.^[2] KPV is a C-terminal fragment of alpha-melanocyte stimulating hormone with potent anti-inflammatory properties, making it a candidate for treating inflammatory skin conditions like atopic dermatitis and psoriasis.

The study tested iontophoresis alone, microneedle pretreatment alone, and the combination. KPV carries a positive charge below pH 7.0, enabling anodal iontophoresis. The combination of microneedle pretreatment followed by iontophoresis achieved significantly higher skin flux than either method alone, creating micropores that the electric current then drove peptide molecules through. This combination strategy has become a template for subsequent research.

GLP-1 Receptor Agonists

Chen et al. (2025) developed a transdermal delivery system for liraglutide, a GLP-1 receptor agonist used for diabetes and obesity that normally requires daily subcutaneous injection.^[4] The system achieved sustained plasma liraglutide levels sufficient for therapeutic efficacy while avoiding the injection-related pain and needle phobia that limit patient adherence. Liraglutide is a 3.7 kDa acylated peptide, substantially larger than KPV, demonstrating that iontophoresis-based approaches can handle peptides in the therapeutically relevant size range. This work connects to the broader pipeline of oral and non-injection GLP-1 delivery.

Cosmetic and Dermatological Peptides

Mortazavi et al. (2022) reviewed the skin permeability challenge for anti-wrinkle peptides, many of which are marketed in cosmetic products but show poor evidence of actually crossing the stratum corneum.^[7] The review found that most commercial cosmetic peptides lack skin penetration data, making their efficacy claims difficult to evaluate. Iontophoresis and other electrical enhancement methods could bridge this gap, delivering peptides that currently sit on the skin surface into the dermis where their molecular targets (collagen-producing fibroblasts, melanocytes) reside.

Enabling Technologies: Computational Optimization

Two 2026 studies illustrate how computational approaches are accelerating transdermal peptide design.

Du et al. (2026) used computational simulation to identify physicochemical properties that determine skin permeability, then designed skin-penetrating peptides optimized for transdermal absorption of melanoma therapeutics.^[3] Among cell-penetrating peptides screened, penetratin exhibited the highest permeability. The team demonstrated that a penetratin-based delivery system could carry anti-cancer agents through the skin and into melanoma tumors in a mouse model, bypassing the need for systemic administration entirely.

Wang et al. (2026) optimized cationic peptide carriers for transdermal siRNA delivery in psoriasis using in silico modeling.^[8] Their computational approach predicted peptide carrier diffusion within the stratum corneum, enabling rapid screening of candidates with transdermal delivery capabilities before committing to expensive synthesis and testing. The optimized peptide carriers successfully delivered siRNA to psoriatic skin, reducing inflammatory markers.

Yang et al. (2026) published a comprehensive review classifying transdermal peptides into five structural categories: short peptides, linear peptides, cyclic peptides, cationic peptides, and amphipathic peptides.^[5] Each category has distinct skin penetration mechanisms and limitations. Cationic peptides (like TAT and poly-arginine) penetrate via electrostatic interaction with negatively charged skin components. Amphipathic peptides disrupt lipid organization in the stratum corneum. This classification framework provides a rational basis for selecting or designing carrier peptides for iontophoretic delivery.

Combination Approaches: Iontophoresis Plus Microneedles

The combination of iontophoresis with microneedle pretreatment has emerged as the most effective strategy for transdermal peptide delivery. Microneedles create physical channels through the stratum corneum (bypassing the main barrier), while iontophoresis provides an active driving force to push peptides through these channels into deeper tissue.

Hasan et al. (2026) addressed a critical manufacturing challenge for this approach: maintaining peptide stability during microneedle patch fabrication.^[6] Conventional microneedle manufacturing exposes peptides to heat, mechanical stress, and polymer interactions that can denature them. Their emulsion-based formulation protected peptide therapeutics during the fabrication process, maintaining biological activity in the finished patches. This solves a practical barrier that has hindered the translation of microneedle-peptide combinations from laboratory to commercial products. For more on standalone microneedle technology, see the pillar article on microneedle patches.

Carrier-free delivery systems are also advancing. Chung et al. (2026) developed a topical system that uses a skin-penetrating peptide as both the delivery vehicle and the active therapeutic, eliminating the need for separate carrier molecules.^[9] The peptide itself possessed intrinsic anti-inflammatory activity while simultaneously enabling transdermal delivery of co-formulated finasteride for hair growth, demonstrating that peptides can serve as both drug and delivery vehicle.

Iontophoresis in the Transdermal Delivery Landscape

Iontophoresis is one of several technologies competing to solve the peptide injection problem. Each has distinct strengths.

Microneedle patches create physical channels through the skin and can deliver peptides in a single application, but they deliver a fixed dose determined at manufacturing. Iontophoresis allows real-time dose adjustment by varying the current, making it better suited for peptides that require individualized dosing. Oral peptide delivery avoids the skin entirely but faces the far more hostile environment of the gastrointestinal tract, where proteases and acidic pH destroy most peptides before absorption.

The most advanced transdermal peptide approach uses topical peptide formulations with chemical penetration enhancers, which are simpler and cheaper than electrical devices but limited to small, lipophilic peptides. For larger, charged peptides that make up the majority of therapeutic candidates, electrical enhancement through iontophoresis or electroporation remains necessary.

Wearable iontophoresis devices represent the convergence of these technologies. Thin, flexible patches that incorporate both microneedle arrays and iontophoretic electrodes could provide programmable, patient-controlled peptide delivery without clinical visits. Several such devices are in development, though none has reached regulatory approval for peptide delivery.

Limitations and Open Questions

Despite two decades of research, iontophoretic peptide delivery has not reached widespread clinical use. Several barriers persist.

Size ceiling. Most successful demonstrations involve peptides under 5 kDa. Larger peptides and proteins face exponentially lower transport rates through the skin, even with electrical enhancement. Whether iontophoresis can achieve therapeutic plasma concentrations for larger biologics (antibodies, larger protein drugs) remains unproven.

Skin variability. Skin thickness, hydration, hair follicle density, and sebaceous gland activity vary across body sites, between individuals, and with age. These variables affect iontophoretic transport rates unpredictably, making dose standardization challenging. The same device and current setting may deliver different amounts of peptide to different patients.

Stability. Peptides in contact with skin surfaces and subject to electric current may undergo degradation through oxidation, aggregation, or enzymatic breakdown by skin proteases. Formulation strategies (pH optimization, protease inhibitors, encapsulation) add complexity and cost.

Regulatory pathway. Iontophoretic peptide delivery devices are combination products (drug plus device), which face a more complex regulatory review process than either a drug or a device alone. The FDA and EMA have not approved any iontophoretic peptide delivery product, though the underlying device technology is well-established for small molecules.

Bioequivalence. Demonstrating that a transdermal peptide delivery system produces the same pharmacokinetic profile as subcutaneous injection is technically demanding. Plasma concentration curves from iontophoretic delivery are typically flatter and more sustained than the sharp peak-and-trough pattern from injection. This is pharmacologically advantageous for many peptides (smoother drug levels reduce side effects), but it complicates regulatory bioequivalence testing because the profiles look fundamentally different. The FDA has not yet established clear bioequivalence guidance for iontophoretic peptide products, which adds regulatory uncertainty for companies developing these systems.

Cost and complexity. Iontophoretic devices add hardware costs (electrodes, power supply, control circuitry) on top of the peptide drug itself. For the technology to compete with conventional injection, the device costs must be low enough that the combination remains economically viable, especially for chronic therapies that require frequent dosing. Advances in printed electronics and flexible circuit manufacturing are driving device costs down, but they have not yet reached the price point needed for broad adoption.

The field continues to develop solutions to each of these barriers, with computational design, combination devices, and novel formulations progressively expanding the range of peptides that can be delivered through the skin.

The Bottom Line

Iontophoresis uses mild electric current to drive peptide molecules through the skin barrier without needles. The technology has successfully delivered anti-inflammatory tripeptides, GLP-1 receptor agonists, and skin-penetrating carrier peptides in research settings. Combination with microneedles and computational optimization of carrier peptides are the most active frontiers. The gap to clinical use remains significant: skin variability, peptide stability, and combination-product regulatory complexity have slowed translation from laboratory demonstrations to approved products.

Frequently Asked Questions

What is iontophoresis for drug delivery?

Iontophoresis is a non-invasive technique that uses mild electric current (0.1-0.5 mA/cm2) to drive charged drug molecules through the skin. Two electrodes are placed on the skin surface, and the electric field pushes charged peptides through the stratum corneum via electromigration and electroosmosis.^[1] The FDA has cleared iontophoretic devices for small molecule delivery for decades.

Can peptides be delivered through the skin?

Yes, but with difficulty. Peptides are typically too large and polar to cross the skin barrier passively. Iontophoresis, microneedles, and skin-penetrating carrier peptides have all demonstrated transdermal peptide delivery in research settings. The combination of microneedle pretreatment with iontophoresis achieves significantly higher peptide flux than either method alone.^[2]

Is iontophoresis painful?

At the current densities used for drug delivery (0.1-0.5 mA/cm2), patients typically feel only a mild tingling sensation. These currents are well below the threshold for pain or tissue damage. Mild skin redness at the electrode site is the most commonly reported side effect and typically resolves within hours.^[1]

Can GLP-1 drugs be delivered through patches?

Research is moving in that direction. Chen et al. (2025) achieved sustained plasma levels of liraglutide (a GLP-1 receptor agonist) through transdermal delivery, demonstrating proof-of-concept for needle-free GLP-1 administration.^[4] No transdermal GLP-1 product is commercially available yet, but the potential to eliminate injection-related adherence problems is driving active development.

How does iontophoresis compare to microneedle patches?

They work through different mechanisms. Microneedles create physical channels through the skin barrier. Iontophoresis uses electric current to actively drive molecules through the skin. Combined, they are more effective than either alone: microneedles open the barrier while iontophoresis provides ongoing driving force.^[2][6] Both are non-invasive alternatives to injection.

Why aren't iontophoretic peptide patches available yet?

Three main barriers: skin variability makes dose standardization difficult across patients and body sites; peptide stability during manufacturing and storage requires specialized formulations; and the combination drug-device regulatory pathway is more complex than for drugs or devices alone. Research continues to address each barrier, with computational design and novel formulations advancing the field.^[5]